

To: Business Editor

[For Immediate Release]



Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司

Powder Pharmaceuticals Hong Kong as the Manufacturing Site for Zingo™ is Approved by FDA

***The First Medical Device Combination Manufacturing Site in Hong Kong
and Product manufactured for US Market Obtained FDA Approval***

[30 July 2013, Hong Kong] Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or the "Group", Stock Code: 950) an integrated research-driven and market-oriented pharmaceutical group in China is pleased to announce that Powder Pharmaceuticals, Incorporated ("PPI"), an associated company of the Group, has successfully obtained an approval letter on 24 July 2013 from U.S. Food and Drug Administration ("FDA") regarding the supplemental new drug application for PPI's Hong Kong Manufacturing site for Zingo™ Powder Intradermal Injection system .

The approval letter stated that the supplemental new drug application for PPI's Hong Kong Manufacturing site of Zingo™ Powder Intradermal Injection system, which transact in U.S. market is approved by FDA. PPI Hong Kong GMP Manufacturing Facility is the first and only facility in Hong Kong that is successfully obtained the approval from FDA. It marks a historic moment to Hong Kong pharmaceutical's development as Zingo™ became the first product approved by FDA that manufactured in Hong Kong for US market..

Dr. Benjamin Li, Chief Executive Officer of the Group and PPI, said, "The approval by the FDA to relaunch Zingo™ in U.S is not only a monumental milestone to PPI, but also symbolizes a breakthrough for Hong Kong's effort to become a biotech hub. PPI as well as Hong Kong will be proud of having the first Drug/Medical Device combination manufacturing site that is approved by FDA. Looking ahead, Lee's Pharm and its subsidiaries will continue to dedicate to the biopharmaceutical technology development and pursue global cooperation with accomplished partners and organizations, to provide a better and higher standard of pharmaceutical products and improve the health and quality of life."

- End -

博達浩華國際財經傳訊集團

Porda Havas International Finance Communications Group

Units 2009-2018, 20/F, Shui On Centre, 6-8 Harbour Road, Wanchai, HK 香港灣仔港灣道6-8號瑞安中心20樓2009-2018室
T : (852) 3150 6788 F : (852) 3150 6728

www.pordahavas.com

About Zingo™

Zingo™ is the first needleless, painless powder injection system to be approved for analgesia at an IV/cannula access site. The rapid onset of analgesia in 1-3 minutes provides care givers and patients the opportunity for a pain-free and needle-free access procedure. Zingo™ is approved for use in children over 3 years of age and in adults. Clinical trials have shown a statistical difference in pain scores during needle access procedures when using Zingo™ versus a placebo system.

About Powder Pharmaceuticals, Incorporated (“PPI”)

PPI is a privately held company based in Hong Kong that is developing products that utilize a proprietary needleless, painless, powder delivery technology. Powder Pharmaceuticals intends to supply Zingo™ globally through international business partners. PPI has submitted the amendment with FDA for approval of the production of Zingo™ in the new Hong Kong manufacturing facility since 29 October 2012. This approval is the major milestone achievement for PPI. PPI hope to relaunch Zingo™ in the U.S. in early 2014.

About Lee's Pharmaceutical Holdings Limited (“Lee's Pharm”)

Lee's Pharm is a research-based Hong Kong biopharmaceutical company listed in Hong Kong with over 19 years operation in China's pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with over 20 international companies and currently has 14 products in the market place. Lee's Pharm focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. Lee's Pharm development program is lauded with 30 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies and aspiring to combat diseases such as liver cancer and pulmonary hypertension. The mission of Lee's Pharm is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life.

Additional information about Lee's Pharm is available at www.leespharm.com.

This press release is issued by **Porda Havas International Finance Communications Group** for and on behalf of **Lee's Pharmaceutical Holdings Limited**. For further information, please contact:

Porda Havas International Finance Communications Group

Ms. Keely Chan	+852 3150 6760	keely.chan@pordahavas.com
Ms. Cherry Cheung	+852 3150 6773	cherry.cheung@pordahavas.com
Ms. Ka Wai Li	+852 3150 6715	kawai.li@pordahavas.com
Ms. Mandy Zhang	+852 3150 6765	mandy.zhang@pordahavas.com
Mr. Brian Su	+852 3150 6795	brian.su@pordahavas.com

Lee's Pharmaceutical Holdings Limited

Tel: +852 2314 1282

Email: info@leespharm.com

博達浩華國際財經傳訊集團

Porda Havas International Finance Communications Group

Units 2009-2018, 20/F, Shui On Centre, 6-8 Harbour Road, Wanchai, HK 香港灣仔港灣道6-8號瑞安中心20樓2009-2018室
T : (852) 3150 6788 F : (852) 3150 6728

www.pordahavas.com